Human papillomavirus vaccines for the treatment of cervical cancer

References

• zur Hausen H, de Villiers EM. Human papilloma viruses. Annu. Rev. Microbiol.48, 427–447 (1994).
   PubMed Web of Science ®Google Scholar
• Bosch FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J. Natl. Cancer Inst.87, 796–802 (1995).
   PubMed Web of Science ®Google Scholar
• Campion MJ. Clinical manifestations and natural history of genital papillomavirus infections. Obstet. Gynecol. Clin. North Am.14, 363–388 (1987).
   PubMed Web of Science ®Google Scholar
• Syrjanen KJ. Biology of human papillomavirus infections and their role in squamous cell carcinogenesis. Med. Biol.65, 21–39 (1987).
   PubMedGoogle Scholar
• Lorincz AT, Temple GF, Kurman RJ et al. Oncogenic association of specific papillomavirus types with cervical neoplasia. J. Natl. Cancer Inst..79, 671–677 (1987).
   PubMed Web of Science ®Google Scholar
• Cullen AP, Reid R, Campion M, Lorincz AT. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasve cervical neoplasia. J. Virol.65, 606–612 (1991).
   PubMed Web of Science ®Google Scholar
• Munger K, Phelps WC, Bubb V et al. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol.63, 4417–4421 (1989).
   PubMed Web of Science ®Google Scholar
• Dyson N, Howley PM, Munger K, Harlow E. The human papillomavirus-16 E7 oncoprotein is able to bind the retinoblastoma gene product. Science243, 934–937 (1989).
   PubMed Web of Science ®Google Scholar
• Scheffner M, Munger K, Bryne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA88, 5523–5527 (1991).
   Google Scholar
• Werness BA, Levine AJ, Howley PM. Association of HPV type 16 and 18 E6 protein with p53. Science248, 76–79 (1990).
   PubMed Web of Science ®Google Scholar
• Heck DV, Yee CL, Howley PM, Münger K. Efficiency of binding to the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses.Proc. Natl. Acad. Sci. USA89, 4442–4446 (1992).
   PubMed Web of Science ®Google Scholar
• Münger K, Werness BA, Dyson N et al. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J.8, 4099–4105 (1989).
   PubMed Web of Science ®Google Scholar
• Stoler MH, Rhodes CR, Whitbeck A et al. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum. Pathol.23, 117–128 (1992).
   PubMed Web of Science ®Google Scholar
• Casas L, Galvan SC, Ordonez RM et al. Asian-american variants of human papillomavirus type 16 have extensive mutations in the E2 gene and are highly amplified in cervical carcinomas. Int. J. Cancer 83, 449–455 (1999).
   PubMed Web of Science ®Google Scholar
• Stevenson M, Hudson LC, Burns JE et al. Inverse relationship between the expression of the human papillomavirus type 16 transcription factor E2 and virus DNA copy number during the progression of cervical intraepithelial neoplasia. J. Gen. Virol.81, 1825–1832 (2000).
   PubMed Web of Science ®Google Scholar
• Olatunbosun O, Deneer H, Pierson R. Human papillomavirus DNA detection in sperm using polymerase chain reaction. Obstet. Gynecol. 97, 357–360 (2001).
   PubMed Web of Science ®Google Scholar
• de Villiers EM, Wagner D, Schneider A et al. Human papillomavirus DNA in women without and with cytological abnormalities: results of a 5-year follow-up study. Gynecol. Oncol. 44, 33–39 (1992).
   PubMed Web of Science ®Google Scholar
• Schiffman MH, Castle P. Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. J. Natl. Cancer Inst. 95, E2 (2003).
   PubMedGoogle Scholar
• Kirnbauer R, Taub J, Greenstone H et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol.67, 6929–6936 (1993).
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Booy F, Cheng N et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA89, 12180–12184 (1992).
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Chandrachud LM, O’Neil BW et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology219, 37–44 (1996).
   PubMed Web of Science ®Google Scholar
• Harro CD, Pang Y, Roden RB et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93, 284–292 (2001).
   PubMed Web of Science ®Google Scholar
• Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645–1651 (2002).
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre Phase II efficacy trial. Lancet Oncol6, 271–278 (2005).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet367, 1247–1255 (2006).
   PubMed Web of Science ®Google Scholar
• de Gruijl TD, Bontkes HJ, Stukart MJ et al. T cell proliferative responses against 18 human papilomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. J. Gen. Virol.77, 2183–2191 (1996).
   PubMed Web of Science ®Google Scholar
• Petry KU, Scheffel D, Bode U et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int. J. Cancer57, 836–840 (1994).
   PubMed Web of Science ®Google Scholar
• Chirgwin KD, Feldman J, Augenbraun M et al. Incidence of venereal warts in human immunodeficiency virus-infected and uninfected women. J. Infect. Dis.172, 235–238 (1995).
   PubMed Web of Science ®Google Scholar
• Iwatsuki K, Tagami H, Takigawa M, Yamada M. Plane warts under spontaneous regression. Immunopathologic study on cellular constituents leading to the inflammatory reaction. Arch. Dermatol.122, 655–659 (1986).
   PubMedGoogle Scholar
• Apple RJ, Erlich, HA Klitz W et al. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat. Genet.6, 157–162 (1994).
   PubMed Web of Science ®Google Scholar
• Odunsi K, Terry G, Ho L et al. Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. Int. J. Cancer 67, 595–602 (1996).
   PubMed Web of Science ®Google Scholar
• Tsukui T, Hildesheim A, Schiffman MH et al. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res.56, 3967–3974 (1996).
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Stites DP, Farhat S et al. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J. Infect. Dis.175, 927–931 (1997).
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Stites DP, Patel S et al. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J. Infect. Dis.182, 595–598 (2000).
   PubMed Web of Science ®Google Scholar
• Sarkar AK, Tortolero-Luna G, Follen M, Sastry KJ. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV 16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study. Gynecol. Oncol. 99, S251–S261 (2005).
   PubMed Web of Science ®Google Scholar
• Kim TW, Hung CF, Boyd DA et al. Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res.64, 400–405 (2004).
   PubMed Web of Science ®Google Scholar
• Kim TW, Hung CF, Kim JW et al. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. Hum. Gene Ther.15, 167–177 (2004).
   PubMed Web of Science ®Google Scholar
• Cheng WF, Hung CF, Hsu KF et al. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum. Gene Ther.13, 553–568 (2002).
   PubMed Web of Science ®Google Scholar
• Hung CF, Cheng WF, Hsu KF et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res.61, 3698–3703 (2001).
   PubMed Web of Science ®Google Scholar
• Lamikanra A, Pan ZK, Isaacs SN, Wu TC, Paterson Y. Regression of established human papillomavirus type 16 (HPV 16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV 16 E7 correlates with enhanced CD8+ T-cell responses that home to the tumor site. J. Virol.75, 9654–9664 (2001).
   PubMed Web of Science ®Google Scholar
• Liu DW, Tsao YP, Kung JT et al. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J. Virol.74, 2888–2894 (2000).
   PubMed Web of Science ®Google Scholar
• Ahn WS, Bae SM, Kim TY et al. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Hum. Gene Ther.14, 1389–1399 (2003).
   PubMed Web of Science ®Google Scholar
• Kim TY, Myoung HJ, Kim JH et al. Both E7 and CpG-ODN are required for protective immunity against challenge with human papillomavirus 16 (E6/E7)-immortalized tumor cells: Involvement of CD4+ and CD8+ T cells in protection. Cancer Res.62, 7234–7240 (2002).
   PubMed Web of Science ®Google Scholar
• Kim MS, Sin JI. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model. Immunol116, 255–266 (2005).
   PubMed Web of Science ®Google Scholar
• Fernando GJP, Murray B, Zhou J, Frazer IH. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin. Exp. Immunol.115, 397–403 (1999).
   PubMed Web of Science ®Google Scholar
• Cui Z, Huang L. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol. Immunother.54, 1180–1190 (2005).
   PubMed Web of Science ®Google Scholar
• Thompson HS, Davies ML, Holding FP et al. Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine17, 40–49 (1999).
   PubMed Web of Science ®Google Scholar
• de Jong A, O’Neill T, Khan AY et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine20, 3456–3464 (2002).
   PubMed Web of Science ®Google Scholar
• Hallez S, Simon P, Maudoux F et al. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPVpositive cervical intraepithelial neoplasia. Cancer Immunol. Immunother.53, 642–650 (2004).
   PubMed Web of Science ®Google Scholar
• Greenfield I, Nickerson J, Penman S, Stanley M. Human papillomavirus 16 E7 protein is associated with the nuclear matrix. Proc. Natl. Acad. Sci. USA88, 11217–11221 (1991).
   PubMed Web of Science ®Google Scholar
• Reinstein E, Scheffner M, Oren M, Ciechanover A, Schwartz A. Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene19, 5944–5950 (2000).
   PubMed Web of Science ®Google Scholar
• Kanda T, Zanma S, Watanabe S, Furuno A, Yoshiike K. Two immunodominant regions of the human papillomavirus type 16 E7 protein are masked in the nuclei of monkey COS-1 cells. Virology182, 723–731 (1991).
   PubMed Web of Science ®Google Scholar
• Ji H, Wang TL, Chen CH et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum. Gene Ther.10, 2727–2740 (1999).
   PubMed Web of Science ®Google Scholar
• Smahel M, Sima P, Ludvikova V, Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology281, 231–238 (2001).
   PubMed Web of Science ®Google Scholar
• Higgins TJ, Herold KM, Arnold RL, McElhiney SP, Shroff KE, Pachuk CJ. Plasmid DNA-expressed secreted and nonsecreted forms of herpes simplex virus glycoprotein D2 induce different types of immune responses. J. Infect. Dis.182, 1311–1320 (2000).
   PubMed Web of Science ®Google Scholar
• Strasser JE, Arnold RL, Pachuk C, Higgins TJ, Bernstein DI. Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs. J. Infect. Dis.182, 1311–1320 (2000).
   PubMed Web of Science ®Google Scholar
• Cheung YK, Cheng SC, Sin FW, Xie Y. Plasmid encoding papillomavirus type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection. Vaccine23, 629–638 (2004).
   PubMed Web of Science ®Google Scholar
• Cheng WF, Hung CF, Chai CY et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J. Clin. Invest.108, 669–678 (2001).
   PubMed Web of Science ®Google Scholar
• Hung CF, He L, Juang J, Lin TJ, Ling M, Wu TC. Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J. Virol76, 2676–2682 (2002).
   PubMed Web of Science ®Google Scholar
• Hung CF, Cheng WF, He L et al. Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res.63, 2393–2398 (2003).
   PubMed Web of Science ®Google Scholar
• Hsu KF, Hung CF, Cheng WF et al.. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther.8, 376–383 (2001).
   PubMed Web of Science ®Google Scholar
• Suzue K, Young RA. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J. Immunol.156, 873–879 (1996).
   PubMed Web of Science ®Google Scholar
• Anthony LS, Wu H, Sweet H, Turnnir C, Boux LJ, Mizzen, LA. Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule. Vaccine17, 373–383 (1999).
   PubMed Web of Science ®Google Scholar
• Osen W, Peiler T, Ohlschlager P et al. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine19, 4276–4286 (2001).
   PubMed Web of Science ®Google Scholar
• Doan T, Herd K, Ramshaw I, Thomson S, Tindle RW. A polytope DNA vaccine elicits multiple effector and memory CTL responses and protects against human papillomavirus 16 E7-expressing tumour. Cancer Immunol. Immunother.54, 157–171 (2005).
   PubMed Web of Science ®Google Scholar
• Sin JI Kim JJ, Boyer JD, Higgins TJ, Ciccarelli RB, Weiner DB. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J. Virol.73, 501–509 (1999).
   PubMed Web of Science ®Google Scholar
• Sin JI, Kim JJ, Arnold RL et al.. Interleukin-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1 type CD4+ T cell mediated protective immunity against HSV-2challenge. J. Immunol.162, 2912–2921 (1999).
   PubMed Web of Science ®Google Scholar
• Kim, TW, Hung CF, Ling M et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J. Clin. Invest.112, 109–117 (2003).
   PubMed Web of Science ®Google Scholar
• Shedlock DJ, Weiner D.B. DNA vaccination: antigen presentation and the induction of immunity. J. Leukoc. Biol.68, 793–806 (2000).
   PubMed Web of Science ®Google Scholar
• Ray NB, Ewalt LC, Lodmell DL. Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protects mice against lethal rabies virus infection. Vaccine15, 892–895 (1997).
   PubMed Web of Science ®Google Scholar
• Wang B, Ugen KE, Srikantan V et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA90, 4156–4160 (1993).
   PubMed Web of Science ®Google Scholar
• Levy MY, Barron LG, Meyer KB, Szoka FC Jr. Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood. Gene Ther.3, 201–211 (1996).
   PubMed Web of Science ®Google Scholar
• Lu S, Santoro JC, Fuller DH et al. Use of DNAs expressing HIV-1 env and noninfectious HIV particles to raise antibody responses in mice. Virology209, 147–154 (1995).
   PubMed Web of Science ®Google Scholar
• Pertmer TM, Eisenbraun MD, McCabe D et al. Gene gun-based nucleic acid immunization; elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine13, 1427–1430 (1995).
   PubMed Web of Science ®Google Scholar
• Trimble C, Lin CT, Hung CF et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector and syringe. Vaccine21, 4036–4042 (2003).
   PubMed Web of Science ®Google Scholar
• Steinman R.M. The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol.9, 271–296 (1991).
   PubMed Web of Science ®Google Scholar
• De Bruijn ML, Schuurhuis DH, Vierboom MP et al. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res.58, 724–731 (1998).
   PubMed Web of Science ®Google Scholar
• Murakami M, Gurski KJ, Marincola FM et al. Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res59, 1184–1187 (1999).
   PubMed Web of Science ®Google Scholar
• Kim TG, Kim CH, Won EH et al. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific anti-tumor immunity in a HPV 16 (E6/E7)-associated tumor animal model. Immunol.112, 117–125 (2004).
   PubMed Web of Science ®Google Scholar
• Santin AD, Hermonat PL, Ravaggi A et al.. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J. Virol.73, 5402–5410 (1999).
   PubMed Web of Science ®Google Scholar
• Rudolf MP, Fausch SC, Da Silva DM, Kast WM. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J. Immunol.166, 5917–5924 (2001).
   PubMed Web of Science ®Google Scholar
• Tillman BW, Hayes TL, DeGruijl TD et al. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res.60, 5456–5463 (2000).
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Liu Y, Salati E et al. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur. J. Immunol.32, 30–38 (2002).
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Gokden M et al. Vaccination with HPV-8 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. New Engl. J. Med.346, 1752–1753 (2002).
   PubMed Web of Science ®Google Scholar
• Ferrara A, Nonn M, Sehr P et al.. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J. Cancer Res. Clin. Oncol.129, 521–530 (2003).
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Palmieri M et al. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol. Oncol. 100, 469–478 (2006).
   PubMed Web of Science ®Google Scholar
• He Z, Wlazlo AP, Kowalczyk DW et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV 16. Virology270, 146–161 (2000).
   PubMed Web of Science ®Google Scholar
• Borysiewicz LK, Fiander A, Nimako M et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347, 1523–1527 (1996).
   PubMed Web of Science ®Google Scholar
• Kaufmann AM, Stern PL, Rankin EM et al.. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-8 E6 and E7 genes, in women with progressive cervical cancer. Clin. Cancer Res.8, 3676–3685 (2002).
   PubMed Web of Science ®Google Scholar
• Garcia-Hernandez E, Gonzalez-Sanchez JL, andrade-Manzano A et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther.13, 592–597 (2006).
   PubMed Web of Science ®Google Scholar
• Krul MR, Tijhaar EJ, Kleijne JA et al. Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains. Cancer Immunol. Immunother.43, 44–48 (1996).
   PubMed Web of Science ®Google Scholar
• Di Fabio S, Medaglini D, Rush CM et al. Vaginal immunization of Cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV 16 antigens. Vaccine16, 485–492 (1998).
   PubMed Web of Science ®Google Scholar
• Gunn GR, Zubair A, Peters, C et al.Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV 16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV 16. J. Immunol.167, 6471–6479 (2001).
   PubMed Web of Science ®Google Scholar
• Bermudez-Humaran LG, Cortes-Perez NG, Lefevre F et al. A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J. Immunol.175, 7297–7302 (2005).
   PubMed Web of Science ®Google Scholar
• Feltkamp MC, Smits HL, Vierboom MP et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol.23, 2242–2249 (1993).
   PubMed Web of Science ®Google Scholar
• Zwaveling S, Ferreira Mota SC, Nouta J et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol.169, 350–358 (2002).
   PubMed Web of Science ®Google Scholar
• Cui Z, Qiu F. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol. Immunother.54, 1180–1190 (2005).
   PubMed Web of Science ®Google Scholar
• Muderspach L, Wilczynski S, Roman L et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res.6, 3406–3416 (2000).
   PubMed Web of Science ®Google Scholar
• van Driel WJ, Ressing ME, Kenter GG et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a Phase I–II trial. Eur. J. Cancer 35, 946–952 (1999).
   PubMed Web of Science ®Google Scholar
• Kono K, Ressing ME, Brandt RM et al. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin. Cancer Res.2, 1825–1828 (1996).
   PubMed Web of Science ®Google Scholar
• Ritz U, Momburg F, Pilch H et al.. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int. J. Oncol.19, 1211–1220 (2001).
   PubMed Web of Science ®Google Scholar
• Bae SH, Park YJ, Park JB et al. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin. Cancer Res.13(1) (2006) (In Press).
   PubMed Web of Science ®Google Scholar
• Sin JI, Hong SH, Park YJ et al.. Antitumor therapeutic effects of E7 subunit and DNA vaccines in an animal cervical cancer model: antitumor efficacy of E7 therapeutic vaccines is dependent on tumor sizes, vaccine doses and vaccine delivery routes. DNA Cell Biol.25, 277–286 (2006).
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C, Anderson, DE. Regulatory cells and human cancer. Semin. Cancer Biol.16, 98–105 (2006).
   PubMed Web of Science ®Google Scholar
• Comes A, Rosso O, Orengo AM et al. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J. Immunol.176, 1750–1758 (2006).
   PubMed Web of Science ®Google Scholar
• Prasad SJ, Farrand KJ, Matthews SA et al. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J. Immunol.174, 90–98 (2005).
   PubMed Web of Science ®Google Scholar
• Gray CP, Arosio P, Hersey P. Association of increased levels of heavy-chain ferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanoma. Clin. Cancer Res.9, 2551–2559 (2003).
   PubMed Web of Science ®Google Scholar
• Liyanage UK, Moore TT, Joo HG et al.. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol.169, 2756–2761 (2002).
   PubMed Web of Science ®Google Scholar
• Wolf AM, Wolf D, Steurer M et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res.9, 606–612 (2003).
   PubMed Web of Science ®Google Scholar